IL273528B2 - Long-acting conjugates of glp-2 derivatives - Google Patents

Long-acting conjugates of glp-2 derivatives

Info

Publication number
IL273528B2
IL273528B2 IL273528A IL27352820A IL273528B2 IL 273528 B2 IL273528 B2 IL 273528B2 IL 273528 A IL273528 A IL 273528A IL 27352820 A IL27352820 A IL 27352820A IL 273528 B2 IL273528 B2 IL 273528B2
Authority
IL
Israel
Prior art keywords
glp
derivative
lysine
group
region
Prior art date
Application number
IL273528A
Other languages
English (en)
Hebrew (he)
Other versions
IL273528B1 (en
IL273528A (en
Inventor
Sung Youb Jung
In Young Choi
Jaehyuk Choi
Min Young Kim
Original Assignee
Hanmi Pharmaceutical Co Ltd
Sung Youb Jung
In Young Choi
Jaehyuk Choi
Min Young Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd, Sung Youb Jung, In Young Choi, Jaehyuk Choi, Min Young Kim filed Critical Hanmi Pharmaceutical Co Ltd
Publication of IL273528A publication Critical patent/IL273528A/en
Publication of IL273528B1 publication Critical patent/IL273528B1/en
Publication of IL273528B2 publication Critical patent/IL273528B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL273528A 2017-09-28 2018-09-28 Long-acting conjugates of glp-2 derivatives IL273528B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170126577 2017-09-28
PCT/KR2018/011586 WO2019066586A1 (ko) 2017-09-28 2018-09-28 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체

Publications (3)

Publication Number Publication Date
IL273528A IL273528A (en) 2020-05-31
IL273528B1 IL273528B1 (en) 2025-04-01
IL273528B2 true IL273528B2 (en) 2025-08-01

Family

ID=65902619

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273528A IL273528B2 (en) 2017-09-28 2018-09-28 Long-acting conjugates of glp-2 derivatives

Country Status (22)

Country Link
US (3) US11530249B2 (cg-RX-API-DMAC7.html)
EP (1) EP3689898B1 (cg-RX-API-DMAC7.html)
JP (2) JP7751381B2 (cg-RX-API-DMAC7.html)
KR (2) KR102681143B1 (cg-RX-API-DMAC7.html)
CN (1) CN111433221B (cg-RX-API-DMAC7.html)
AR (1) AR113258A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018339210B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020006189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3084326A1 (cg-RX-API-DMAC7.html)
DK (1) DK3689898T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090571A1 (cg-RX-API-DMAC7.html)
ES (1) ES3075688T3 (cg-RX-API-DMAC7.html)
FI (1) FI3689898T3 (cg-RX-API-DMAC7.html)
IL (1) IL273528B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004453A (cg-RX-API-DMAC7.html)
PH (1) PH12020550105A1 (cg-RX-API-DMAC7.html)
PT (1) PT3689898T (cg-RX-API-DMAC7.html)
SA (1) SA520411644B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202002563WA (cg-RX-API-DMAC7.html)
TW (2) TWI794897B (cg-RX-API-DMAC7.html)
WO (1) WO2019066586A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202001888B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
EP4082561A4 (en) * 2019-12-24 2024-02-07 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating metabolic bone diseases, comprising glp-2 or conjugate thereof
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
CN115697375A (zh) * 2020-04-03 2023-02-03 韩美药品株式会社 预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物
IL298298A (en) 2020-05-22 2023-01-01 Hanmi Pharm Ind Co Ltd A liquid formulation of a long-acting conjugate of glp–2
CA3182260A1 (en) 2020-06-09 2021-12-16 Gleb Feldman Manufacture, formulation and dosing of apraglutide
CA3201916A1 (en) * 2020-12-24 2022-06-30 Hanmi Pharm. Co., Ltd. Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome
US20250276044A1 (en) * 2022-04-18 2025-09-04 Hanmi Pharm. Co., Ltd. COMBINATION THERAPY COMPRISING GLP-2, AND INSULINOTROPIC PEPTIDE, TNFa INHIBITOR, OR BOTH FOR PREVENTING OR TREATING BOWEL DISEASE
JP2026501948A (ja) 2022-12-23 2026-01-19 ハンミ ファーマシューティカル カンパニー リミテッド Glp-2誘導体又はその持続型結合体を含む移植片対宿主病の予防又は治療用薬学的組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103087A1 (en) * 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
WO2010042145A1 (en) * 2008-09-19 2010-04-15 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
KR20110093924A (ko) * 2005-05-04 2011-08-18 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(glp-2) 유사체
KR20120043205A (ko) * 2010-10-26 2012-05-04 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드?2(glp?2)약물 결합체
KR20130078634A (ko) * 2011-12-30 2013-07-10 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
KR20140069131A (ko) * 2011-09-12 2014-06-09 아뮤닉스 오퍼레이팅 인코포레이티드 글루카곤-유사 펩티드-2 조성물 및 이의 제조 및 사용 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
US20090238838A1 (en) * 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103087A1 (en) * 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
KR20110093924A (ko) * 2005-05-04 2011-08-18 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(glp-2) 유사체
WO2010042145A1 (en) * 2008-09-19 2010-04-15 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
KR20120043205A (ko) * 2010-10-26 2012-05-04 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드?2(glp?2)약물 결합체
KR20140069131A (ko) * 2011-09-12 2014-06-09 아뮤닉스 오퍼레이팅 인코포레이티드 글루카곤-유사 펩티드-2 조성물 및 이의 제조 및 사용 방법
KR20130078634A (ko) * 2011-12-30 2013-07-10 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체

Also Published As

Publication number Publication date
US20230090790A1 (en) 2023-03-23
BR112020006189A2 (pt) 2020-10-13
US20200262888A1 (en) 2020-08-20
NZ762962A (en) 2024-07-05
ES3075688T3 (en) 2026-08-06
EP3689898A4 (en) 2021-06-16
AR113258A1 (es) 2020-03-11
CN111433221B (zh) 2024-12-27
EP3689898B1 (en) 2026-04-29
US20220251164A1 (en) 2022-08-11
TWI794897B (zh) 2023-03-01
PT3689898T (pt) 2026-07-16
FI3689898T3 (fi) 2026-07-21
KR102681144B1 (ko) 2024-07-04
KR20190037181A (ko) 2019-04-05
JP7751381B2 (ja) 2025-10-08
US12703730B2 (en) 2026-08-11
ZA202001888B (en) 2021-05-26
JP2020534840A (ja) 2020-12-03
AU2018339210B2 (en) 2023-02-02
SA520411644B1 (ar) 2024-02-25
TWI795443B (zh) 2023-03-11
IL273528B1 (en) 2025-04-01
TW202142560A (zh) 2021-11-16
EP3689898A1 (en) 2020-08-05
MX2020004453A (es) 2020-07-24
DK3689898T3 (da) 2026-07-27
KR102681143B1 (ko) 2024-07-04
KR20240013836A (ko) 2024-01-30
PH12020550105A1 (en) 2020-12-07
WO2019066586A1 (ko) 2019-04-04
US11530249B2 (en) 2022-12-20
AU2018339210A1 (en) 2020-04-16
TW201927806A (zh) 2019-07-16
CN111433221A (zh) 2020-07-17
JP2023138505A (ja) 2023-10-02
CA3084326A1 (en) 2019-04-04
SG11202002563WA (en) 2020-04-29
IL273528A (en) 2020-05-31
EA202090571A1 (ru) 2020-07-30

Similar Documents

Publication Publication Date Title
IL273528B1 (en) Long-acting conjugates of GLP-2 derivatives
JP2020534840A5 (cg-RX-API-DMAC7.html)
Fathi et al. Elastin based cell-laden injectable hydrogels with tunable gelation, mechanical and biodegradation properties
AU2020210919B2 (en) Glycoside-containing peptide linkers for antibody-drug conjugates
Luo et al. Biodegradable multiblock poly [N-(2-hydroxypropyl) methacrylamide] via reversible addition− fragmentation chain transfer polymerization and click chemistry
Geng et al. Site-directed conjugation of “clicked” glycopolymers to form glycoprotein mimics: binding to mammalian lectin and induction of immunological function
KR101770844B1 (ko) 폴리에틸렌 글리콜 기반의 생분해성 수불용성 하이드로겔
You et al. Synthesis of temperature-responsive heterobifunctional block copolymers of poly (ethylene glycol) and poly (N-isopropylacrylamide)
AU650900B2 (en) New linker for bioactive agents
JP4824404B2 (ja) 脂肪族生物分解性リンカーに基づく放出可能なポリマー複合体
RU2009129953A (ru) Инсулинотропный комплекс, в котором использован фрагмент иммуноглобулина
NZ630888A (en) Antibody drug conjugate (adc) purification
JP2015503554A5 (cg-RX-API-DMAC7.html)
JP2010503706A (ja) リジン系ポリマーリンカー
GB2529356A (en) Novel linker and preparation method thereof
CA2558583C (en) Polymer-based compositions and conjugates of hiv entry inhibitors
KR20170071485A (ko) Peg의 일부를 포함하는 이탈기를 포함하는 시약을 사용한, 펩티드 또는 단백질의 접합방법
Reyes-Ortega et al. Smart heparin-based bioconjugates synthesized by a combination of ATRP and click chemistry
Williams et al. RAFT‐Derived Polymer–Drug Conjugates: Poly (hydroxypropyl methacrylamide)(HPMA)–7‐Ethyl‐10‐hydroxycamptothecin (SN‐38) Conjugates
Hakimi et al. Thiolated methylated dimethylaminobenzyl chitosan: A novel chitosan derivative as a potential delivery vehicle
US20050276858A1 (en) Bifunctional-modified hydrogels
Collins et al. Stability enhancing N-terminal PEgylation of oxytocin exploiting different polymer architectures and conjugation approaches
WO2023201335A3 (en) Purified multivalent protein-hyaluronic acid polymer conjugates
Joshi et al. Synthesis of potent inhibitors of anthrax toxin based on poly-L-glutamic acid
JP7851853B2 (ja) 分子内転位を受けるコンジュゲート